The Correlation between Estimated Glomerular Filtration Rate and Parathyroid Hormone Levels in Predialysis-chronic Kidney Disease Adult Patients at Sanglah General Hospital, Bali, Indonesia

Sianny Herawati1, Yenny Kandarini2, I Putu Yuda Prabawa1

1Department of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia; 2Department of Internal Medicine, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia

Abstracts

BACKGROUND: Chronic kidney disease (CKD) is a structural or functional kidney disease for more than 3 months. In predialysis CKD patients, the serum parathyroid hormone levels increase progressively since the early stages of the disease to maintain phosphate homeostasis. Glomerular filtration rate (GFR) has been widely accepted to assess renal function. The GFR assessment is used to determine the CKD stadium.

AIM: This study aims to analyze the correlation between GFR and parathyroid hormone levels in predialysis CKD patients undergoing treatment at Sanglah General Hospital Denpasar.

METHODS: A cross-sectional observational study was conducted among predialysis CKD patients undergoing treatment at Sanglah General Hospital Denpasar who met the inclusion and exclusion criteria. The inclusion criteria were adult patients (≥18 years) who were accepting to participate in the study. Exclusion criteria were patients with predialysis CKD after thyroidectomy and/or parathyroidectomy and liver disease. The parathyroid hormone levels, blood urea nitrogen, creatinine, and GFR were examined and analyzed by SPSS version 17 for Windows.

RESULTS: A total of 77 patients with predialysis CKD in this study obtained a median of e-GFR of 21.09 (4.72–75.80) mL/min/1.73 m². The median level of parathyroid hormone was 82.07 pg/mL (15.83–716.60 pg/mL). Spearman’s correlation analysis results obtained a strong and significant negative correlation between the e-GFR value and parathyroid hormone levels (r = −0.540; p = 0.000).

CONCLUSION: The parathyroid hormone levels assessment could be used as a recommendation in evaluating the CKD progressivity among predialysis adult patients at Sanglah General Hospital, Bali, Indonesia, due to the strong significant correlation.

Introduction

Chronic kidney disease (CKD) is currently increasing and has become a serious health problem [1]. The global prevalence for CKD was 13.4%, with 10.6% at CKD stages 3–5 [2]. Global Burden of Disease 2015 states that kidney disease is the 12th cause of death globally and is projected to be the 5th cause of death in 2040 [3]. Over the past 10 years, the death rate due to CKD has increased by 31.7% [4]. According to the 2018 Basic Health Research (RISKESDAS) data, the population aged ≥15 years diagnosed with chronic kidney failure in Indonesia is 0.38% and for Bali Province, the prevalence of CKD is 0.44%, with the proportion of CKD patients undergoing hemodialysis is 37.04% [5].

Data at the Sanglah Denpasar Central General Hospital (RSUP) in 2018, CKD patients ranked first out of the top 10 cases of all patients visiting the internal medicine polyclinic. In May 2019, the total number of CKD patient visits was 25% of the total patients who visited the internal medicine polyclinic [6].

Secondary hyperparathyroidism is a complication that often occurs in patients with CKD, which is a mineral and bone metabolism disorder known as mineral and bone disorders in CKD (MBD-CKD) [7]. This disorder’s pathogenesis is characterized by increased secretion of parathyroid hormone and hyperplasia of the parathyroid glands in response to low phosphate and serum 1,25-dihydroxy Vitamin D retention [7]. Secondary hyperparathyroidism will cause vascular calcification associated with increased cardiovascular disease mortality [8], [9], [10]. The prevalence and burden of cardiovascular complications increase with decreasing kidney function. The risk of death from cardiovascular disease is 8 times, 2 times greater in patients with stage CKD G5 A3 (estimated glomerular filtration rate [eGFR] <15 ml/min/1.73 m² and urine albumin to creatinine ratio >300 mg/g) than in populations without kidney disease [10].

In predialysis CKD serum, parathyroid hormone levels increase progressively from the early stages of the disease to maintain phosphate homeostasis [11]. Nearly 20% of patients with eGFR >60 mL/min/1.73 m² experienced increased parathyroid hormone levels...
and increased when kidney function deteriorated [12]. The incidence of secondary hyperparathyroidism was reported to increase according to the increase in the CKD stage, namely: 40% at Stage 3, 70% at Stage 4, and> 80% at Stage 5 [8]. Research by de Boer et al. found that parathyroid hormone levels have a negative significant correlation with e-GFR (r = −0.48; p < 0.0001) [13]. However, a previous study by de Boer et al. did not mention the etiology diagnosis regarding the CKD-patients in evaluating the parathyroid level. In addition, a multicenter cohort study in predialysis CKD patients found that a persistent increase in serum parathyroid hormone was associated with a worse prognosis independent of baseline serum parathyroid hormone and phosphate values [12].

Kidney Disease Improving Global Outcomes (KDIGO) 2017 recommends routine parathyroid hormone, calcium, and phosphate checks on CKD patients starting from stage 3–5 to prevent or delay complications related to CKD [14]. KDIGO also suggests that MBD-PGK management should be based on serial measurements of parathyroid hormone serum and the tendency to persistently increase parathyroid hormone levels above the upper limit of normal value has more clinical significance than just one measurement [15].

Based on those mentioned above, this study aims to analyze the correlation between e-GFR and parathyroid hormone levels in predialysis CKD patients undergoing treatment at Sanglah General Hospital.

Methods

Sample criteria

A cross-sectional observational study has been conducted among 77 CKD patients at the Nephrology Polyclinic and inpatient rooms of the Sanglah General Hospital Denpasar from July 2020 to September 2020. The inclusion criteria were patients who had been diagnosed with CKD and have not undergone dialysis. Male and female aged ≥ 18 years who are participating in this study had been signed the informed consent. In comparison, the exclusion criteria in this study included patients with a history of post-thyroidectomy and/or parathyroidectomy as well as a history of chronic liver disease. The sampling technique was carried out consecutively. The etiology of CKD mention in this study was diabetic nephropathy, chronic pyelonephritis, obstructive nephropathy, polycystic kidney, gout nephropathy, and nephrosclerosis.

Variables assessed

e-GFR is GFR measured numerically using the CKD Epidemiology Collaboration (CKD-EPI) formula.

Results

About 77 patients with predialysis CKD followed this study at the Sanglah Hospital Nephrology polyclinic, who met the inclusion and exclusion criteria. The characteristics of CKD patients who are research subjects are shown in Table 1. In this study, the median age of the patients was 61 years. The youngest patient was 23 years old, while the oldest patient was 81 years old. The number of male patients is more than the number of female patients. The patient’s median BMI was 22.9 kg/m², the lowest BMI was 16.3 kg/m², and the highest was 34.4 kg/m² (Table 1).

Based on the CKD stage according to KDIGO 2017, at Stage 2 it was 2.6%, Stage 3a: 9.1%, Stage 3b: 16.9%, Stage 4: 28.6%, and Stage 5: 42.9%. Based on the etiological diagnosis, the patients were diabetic nephropathy 44.2%, chronic pyelonephritis 31.2%, obstructive nephropathy 18.9%, nephrosclerosis 5.2%, polycystic kidney, and uric acid nephropathy, respectively, 1.3% (Table 1). In addition, a total of 77 predialysis CKD patients had a median e-GFR (CKD-EPI) value of 21.09 (4.72–75.80) mL/min/1.73 m².
Table 1: Baseline characteristic of respondents

| Characteristics       | Percentage | Median (min-max) |
|-----------------------|------------|------------------|
| Age (years)           | 61 (23.00–81.00) |                  |
| Gender                |            |                  |
| Male                  | 50 (64.90) |                  |
| Female                | 27 (35.10) |                  |
| BMI (kg/m²)           |            | 22.9 (16.30–34.40) |
| CKD stage (kg/m²)     |            |                  |
| Stadium 2 (60–89)     | 2 (2.60)   |                  |
| Stadium 3a (45–59)    | 7 (9.10)   |                  |
| Stadium 3b (30–44)    | 13 (16.90) |                  |
| Stadium 4 (15–29)     | 22 (28.60) |                  |
| Stadium 5 (>15)       | 33 (42.90) |                  |
| Ecologic diagnosis    |            |                  |
| Diabetic nephropathy  | 34 (44.20) |                  |
| Chronic pyelonephritis| 24 (31.20) |                  |
| Obstructive nephropathy| 13 (16.90)|                  |
| Polycystic kidney     | 1 (1.30)   |                  |
| Gout nephropathy      | 1 (1.30)   |                  |
| Nephrosclerosis       | 4 (5.20)   |                  |
| Predialysis assessment|            |                  |
| e-GFR (CKD-EPI) (mL/min/1.73 m²) | 21.09 (4.72–75.80) |
| Parathyroid hormone (pg/mL) | 82.07 (15.83–716.60) |
| Parathyroid hormone classification (pg/mL) |                  |
| Low (<15)             | 0 (0.00)   |                  |
| Normal (15–65)        | 30 (38.96) |                  |
| High (>65)            | 47 (61.04) |                  |
| BUN (mg/dL)           | 36.60 (11.40–107.90) |                  |
| Serum creatinine (mg/dL) | 2.94 (0.96–10.30) |                  |
| Blood pressure (mmHg) | 120 (120–170) |                  |
| Systole               | 80 (80–90) |                  |
| Diabetes mellitus     |            |                  |
| Yes                   | 48 (62.30) |                  |
| No                    | 29 (37.70) |                  |
| Proteinuria (mg/dL)   | 100.00 (0.00–600.00) |                  |

GFR: Glomerular filtration rate, CKD-EPI: Chronic kidney disease epidemiology collaboration, BMI: Body mass index, BUN: Blood urea nitrogen

Table 2: Spearman correlation test of parathyroid hormone levels to the CKD stages and e-GFR levels in predialysis CKD patients

| Variables | Parathyroid hormone levels (pg/mL) | r | p   |
|-----------|------------------------------------|---|-----|
| CKD stages|                                    | 0.362 | 0.000* |
| e-GFR (mL/min/1.73 m²) |                          | -0.540 | 0.000* |

CKD: Chronic kidney disease, e-GFR: Estimation of glomerular filtration rate, *Statistically significant if p<0.001.

Discussion

CKD is a common condition that refers to a long-term loss of kidney function [16]. CKD in primary care is commonly asymptomatic, and the exact pathology underlying its development is often unknown (as no renal biopsy is usually performed) [16]. It is identified and defined by the presence of an abnormality of kidney structure or function (or both) present for at least 3 months by evaluating the GFR [17]. Several studies have shown that there was a relationship between GFR and parathyroid hormone levels in predialysis-CKD where it could lead to the parathyroid hormone levels increase progressively from the early stages of the disease to maintain phosphate homeostasis and worsening the prognosis [18], [19], [20].

A significant negative correlation was found between the e-GFR value and parathyroid hormone levels in CKD predialysis patients at Sanglah General Hospital, Bali, Indonesia. Research Pala et al. found that 57.5% of their study patients had hyperparathyroidism with a significantly higher frequency of stage four CKD compared to third stage CKD (47.1% third stage CKD, and 89.3% fourth stage CKD, p < 0.001) [21]. A cross-sectional study involving 415 CKD patients in Spain received the median parathyroid hormone at stage three CKD of 86 pg/mL and 120 pg/mL at stage four CKD [22]. In addition, the previous studies by Levin et al. and Wei et al. stated that the prevalence of significantly increased parathyroid hormone levels occurs at eGFR <50 ml/min/1.73 m² [8], [23]. Based on the eGFR group, it can be concluded that the median distribution of parathyroid hormone levels in the eGFR group Stages 2–5 shows a tendency to increase with decreasing eGFR values.

This study also suggests a significant low-positive correlation between the CKD stage and parathyroid hormone levels. Several previous studies also showed a significant correlation between eGFR and parathyroid hormone levels, namely, de Boer et al. (r=-0.48; p<0.0001) and Malawadi et al. (r = −0.718; p < 0.001) [13], [24]. An increase in parathyroid hormone is considered an early marker of MBD-CKD. Examination of parathyroid hormone levels in CKD is a significant predictor of cardiovascular morbidity and mortality, endothelial dysfunction, or systemic inflammation. KDIGO 2017 recommends performing routine parathyroid hormone examinations for CKD patients starting at Stage 3–5 to prevent or delay complications of BMD-CKD [10], [13], [24].

Based on the discussion above, the authors assume that early evaluation of parathyroid hormone evaluation, from the Stage 1, has a significant role in preventing the progressivity of CKD among predialysis adult patients as well as delaying the future complications. However, further study with bigger sample size, longitudinal study, and follow-up evaluation of parathyroid hormone are suggested to clarify the limitation of this study.
Conclusion

The parathyroid hormone levels assessment could be used as a recommendation in evaluating the CKD progressivity among predialysis adult patients at Sanglah General Hospital, Bali, Indonesia, due to the strong significant correlation.

Ethics Consideration

Ethics approval has been received from the Ethics Committee, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia with Number:1613/UN14.2.2.VII.14/LT/2020 prior to the study being conducted.

Author Contribution

All authors equally contributed to the study from the conceptual framework, data gathering, and data analysis until the publication of the study results.

References

1. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-52. https://doi.org/10.1016/s0140-6736(16)32064-5
PMid:27887750

2. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. https://doi.org/10.1371/journal.pone.0158765
PMid:27383068

3. Banerjee D, Jha V. Vitamin D and cardiovascular complications of CKD: What’s next? Clin J Am Soc Nephrol. 2019;14(6):932-4.
PMid:31064752

4. Neuen BL, Chadban SJ, Demaio AR, Johnson DW, Perkovic V. Chronic kidney disease and the global NCDs agenda. BMJ Glob Health. 2017;2(2):e000380. https://doi.org/10.1136/bmjgh-2017-000380
PMid:29225940

5. Indonesia Ministry of Health. National Ministry of Health Reports 2018. Jakarta: National Institute of Health Research and Development; 2018. https://doi.org/10.25133/jipssv27n1.003

6. Sanglah General Hospital, Outpatient Installation Service Report for at Sanglah Hospital Denpasar During May 2019; 2019.

7. Kanal G, Fukagawa M. CKD-MBD (chronic kidney disease-mineral and bone disorder). Gene therapy for secondary hyperparathyroidism. Clin Calcium. 2010;20(7):1052-9.
PMid:20585184

8. Wei Y, Lin J, Yang F, Li X, Hou Y, Lu R, et al. Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease. Exp Ther Med. 2016;12(2):1206-12.
PMid:27446345

9. Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of renal disease. Perm J. 2016;20(3):15-127.
PMid:27479950

10. Bello AK, Alrukhami M, Ashuntantang GE, Basnet S, Rotter RC, Douthat WG, et al. Complications of chronic kidney disease: Current state, knowledge gaps, and strategy for action. Kidney Int Suppl (2011). 2017;7(2):122-9. https://doi.org/10.1016/j.kisu.2017.07.007
PMid:29075426

11. Coen G, Ballanti P, Bonucci E, Calabria S, Costantini S, Ferrannini M, et al. Renal osteodystrophy in predialysis and hemodialysis patients: Comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron. 2002;91(1):103-11. https://doi.org/10.1159/000057611
PMid:12021526

12. Borrelli S, Chiodini P, de Nicola L, Minutolo R, Provenzano M, Garofalo C, et al. Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care. PLoS One. 2018;13(8):e0202417. https://doi.org/10.1371/journal.pone.0202417
PMid:30138402

13. de Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol. 2002;13(11):2762-9. https://doi.org/10.1097/01asn.0000034202.91413.eb
PMid:12397047

14. Erratum: Kidney disease: Improving global outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1-59. Kidney Int Suppl (2011). 2017;7(3):e1. https://doi.org/10.1016/j.kisu.2017.10.001
PMid:30681074

15. Kakuta T, Ishida M, Fukagawa M. Critical governance issue of parathyroid hormone assays and its selection in the management of chronic kidney disease mineral and bone disorders. Ther Apher Dial. 2018;22(3):220-8. https://doi.org/10.1111/1744-9987.12690
PMid:29781225

16. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: A review. JAMA. 2019;322(13):1294-304. https://doi.org/10.1001/jama.2019.14745
PMid:31573641

17. Delaney P, Cavalier E. Staging chronic kidney disease and estimating glomerular filtration rate: An opinion paper about the new international recommendations. Clin Chem Lab Med. 2013;51(10):1911-7. https://doi.org/10.1515/cclm-2013-0223
PMid:23729625

18. Stavroulopoulos A, Porter CJ, Roe SD, Hosking DJ, Cassidy MJ. Relationship between Vitamin D status, parathyroid hormone levels and bone mineral density in patients with chronic kidney disease stages 3 and 4. Nephrology (Carlton). 2008;13(1):63-7. https://doi.org/10.1111/j.1440-1797.2007.00860.x
PMid:18199106

19. Wang WH, Chen LW, Lee CC, Sun CY, Shyu YC, Hsu HR, et al. Association between parathyroid hormone, 25 (OH) Vitamin D, and chronic kidney disease: A population-based
20. Muntner P, Jones TM, Hyre AD, Melamed ML, Alper A, Raggi P, et al. Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin J Am Soc Nephrol. 2009;4(1):186-94. https://doi.org/10.2215/cjn.03050608 PMid:19019998

21. Pala AS, Kaya E, Alagoz S, Trabulus S, Bolayirtli M, Altiparmak MR, et al. Prevalence of Vitamin D deficiency in patients with stage 3/4 chronic kidney disease and its relation to secondary hyperparathyroidism. Turk J Nephrol. 2019;28(2):132-7. PMid:20352364

22. Bureo JC, Arévalo JC, Antón J, Adrados G, Jiménez Morales JL, Robles NR, et al. Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine. Endocrinol Nutr. 2015;62(7):300-5. https://doi.org/10.1016/j.endoen.2015.08.007 PMid:26138703

23. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum Vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-8. https://doi.org/10.1038/sj.ki.5002009 PMid:17091124

24. Malawadi BN, Suma MN, Prashant V, Akila P, Anjalidevi BS, Manjunath S. Secondary hyperparathyroidism in all the stages of chronic kidney disease in Southern Indian population. Int J Pharm Pharm Sci. 2014;6(4):287-90.